» Articles » PMID: 21971610

Mesenchymal Stem Cells Promote Tumor Engraftment and Metastatic Colonization in Rat Osteosarcoma Model

Overview
Journal Int J Oncol
Specialty Oncology
Date 2011 Oct 6
PMID 21971610
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Although mesenchymal stem cells (MSCs) are considered to be the cells of origin for most sarcomas, the role of MSCs as a source of tumor stroma is not fully understood in this tumor type. The current study investigated whether MSCs affect the tumor growth and metastatic ability in rat osteosarcoma model. Results from subcutaneous co-implantation of rat osteosarcoma COS1NR cells, established in our laboratory, with rat MSCs isolated from femur bone marrow showed that the incidence of tumor formation and tumor growth rate was higher until 5 weeks compared to COS1NR cell inoculation alone. However, no difference was observed in tumor growth afterwards and in the number of metastatic nodules at 9 weeks (0.75 vs. 1.2). Intravenous MSC injection at weeks 3 and 5 after subcutaneous inoculation of COS1NR cells significantly increased the number of lung nodules in the group with MSC injection compared to the group without MSC injection (17.33 vs. 2.0), while no difference was observed in subcutaneous tumor growth between those groups. Pathway analysis from gene expression profile identified that genes involved in focal adhesion, cytokine-cytokine receptor and extracellular matrix-receptor pathways such as CAMs (ICAM and VCAM)-integrins were highly expressed in MSCs, possibly participating in the tumor progression of osteosarcoma. These results suggest that MSCs could provide a source of microenvironments for osteosarcoma cells, and might enhance the ability of settlement and colonization which lead to early onset of growth and metastasis, possibly through their activated pathways interaction.

Citing Articles

Beyond conventional therapies: MSCs in the battle against nerve injury.

Song S, Li C, Xiao Y, Ye Z, Rong M, Zeng J Regen Ther. 2025; 28:280-291.

PMID: 39896446 PMC: 11782851. DOI: 10.1016/j.reth.2024.12.017.


Roles of lysophosphatidic acid (LPA) receptor-mediated signaling in cancer cell biology.

Takai M, Mori S, Honoki K, Tsujiuchi T J Bioenerg Biomembr. 2024; 56(4):475-482.

PMID: 38886303 DOI: 10.1007/s10863-024-10028-9.


The intricate interplay between cancer stem cells and cell-of-origin of cancer: implications for therapeutic strategies.

Bamodu O, Chung C, Pisanic 2nd T, Wu A Front Oncol. 2024; 14:1404628.

PMID: 38800385 PMC: 11116576. DOI: 10.3389/fonc.2024.1404628.


Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review).

Yu T, Jiang W, Wang Y, Zhou Y, Jiao J, Wu M Int J Oncol. 2024; 64(4).

PMID: 38390935 PMC: 10919759. DOI: 10.3892/ijo.2024.5628.


Research trends and hotspots in the immune microenvironment related to osteosarcoma and tumor cell aging: a bibliometric and visualization study.

Zhang W, Shao Z Front Endocrinol (Lausanne). 2023; 14:1289319.

PMID: 38027171 PMC: 10663373. DOI: 10.3389/fendo.2023.1289319.